Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aytu Biopharma (AYTU) Enterprise Value (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Enterprise Value for 14 consecutive years, with -$30.0 million as the latest value for Q4 2025.

  • Quarterly Enterprise Value fell 47.2% to -$30.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$30.0 million through Dec 2025, down 47.2% year-over-year, with the annual reading at -$31.0 million for FY2025, 54.71% down from the prior year.
  • Enterprise Value for Q4 2025 was -$30.0 million at Aytu Biopharma, up from -$32.6 million in the prior quarter.
  • The five-year high for Enterprise Value was -$18.2 million in Q1 2025, with the low at -$50.2 million in Q2 2021.
  • Average Enterprise Value over 5 years is -$25.8 million, with a median of -$20.4 million recorded in 2024.
  • The sharpest move saw Enterprise Value soared 61.4% in 2022, then tumbled 62.27% in 2025.
  • Over 5 years, Enterprise Value stood at -$35.3 million in 2021, then surged by 44.72% to -$19.5 million in 2022, then fell by 0.14% to -$19.5 million in 2023, then decreased by 4.45% to -$20.4 million in 2024, then plummeted by 47.2% to -$30.0 million in 2025.
  • According to Business Quant data, Enterprise Value over the past three periods came in at -$30.0 million, -$32.6 million, and -$31.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.